Health policy news

European Medicines Agency: EMA has agreed three changes to human medicines for the treatment of cancer in February 2011.

Added: Tuesday 15 March 2011

New marketing authorisations - Docetaxel Teva Pharma (docetaxel) - Treatment of breast cancer, non-small-cell lung cancer and prostate cancer Withdrawal of marketing authorisation applications - Topotecan SUN (topotecan) - Intended for the treatment of metastatic cancer of the ovary, small-cell lung cancer and cervical cancer Arbitration procedures (non-safety related) - Docetaxel Teva Generics (docetaxel) - Treatment of: breast cancer, non-small-cell lung cancer, prostate cancer, gastric adenocarcinoma and head and neck cancer More details can be found at: